Clin2
NCT05896839Possibly a fitRecruiting

Immunotherapy with prednisone and sirolimus for transplant skin cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Metastatic Basal Cell CarcinomaMetastatic Carcinoma in the SkinMetastatic MelanomaMetastatic Merkel Cell Carcinoma

Treatments studied

Part of Cancer, Infections, Skin clinical trials.

This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
16 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a kidney transplant that is working well, and you are not on dialysis
  • You are 18 years or older (this study excludes children)
  • You have a confirmed non-uveal melanoma, basal cell cancer, Merkel cell cancer, or cutaneous squamous cell cancer that cannot be handled well with standard local treatment
  • Your cancer has at least one measurable spot on scans or exam
  • Your blood counts and organ blood tests meet minimum lab thresholds
  • You must be able to sign informed consent and follow contraception rules if you can become pregnant

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07215988Recruiting
Studying insurance for skin cancer treatment

This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.

Columbus, Ohio
NCT07422779Recruiting
Immunotherapy for advanced melanoma study

This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.

Ljubljana
NCT07576725Not yet recruiting· Phase 2
Low-dose nivolumab for advanced cancer

This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.

Kampala
NCT07426484Recruiting· Phase 4
Testing cosibelimab for advanced skin cancer in specific patients

This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.

Boston, Massachusetts
NCT07740941Not yet recruiting· Phase 2
Neoadjuvant, spare-adjuvant (NASA) in stage IIIB-IV (M1a) melanoma

This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.

Chapel Hill, North Carolina
NCT04204837Recruiting· Phase 2
Nivolumab for advanced skin squamous cell cancer

This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.

Graz

Hear when a new Clinical Stage III Cutaneous Melanoma AJCC v8 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.